Davis Polk advised AstraZeneca PLC in connection with its SEC-registered shelf takedown of $1 billion aggregate principal amount of 1.95% notes due 2019 and $1 billion aggregate principal amount of 4% notes due 2042. The notes were underwritten by Goldman, Sachs & Co., HSBC Securities (USA) Inc., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC.
AstraZeneca is a global, innovation-driven, prescription-based biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for six important areas of health care: cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory and inflammation.
The Davis Polk corporate team included partner Jeffrey M. Oakes and associates Roman Ajzen, Leo Borchardt and Ashley L. Flucas. Partner John D. Paton and associate Sarah Joy provided tax advice. Claire Lim was the legal assistant on the transaction. All members of the Davis Polk team are based in the London office.
